Stay updated with breaking news from Teplizumab Tzield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The preservation of insulin-producing beta cells is just one of the benefits of teplizumab, also known as Tzield, a phase 3 trial shows.
Secondary endpoints including insulin use and glucose levels weren't met but trended in a positive direction.
The US Food and Drug Administration approved of a drug that delays Type 1 diabetes. The medical industry has been dedicated not just to healing the sick but finding ways to avoid being ill in the first place.
FRIDAY, Nov. 18, 2022 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved the first drug that could delay the development of type 1 diabetes (T1D).